HIV Alert!

New CDC MMWR report on antibiotic-resistant gonorrhea includes concerning findings for azithromycin - one of two drugs in the only recommended treatment regimen

Centers for Disease Control and Prevention (CDC), July 14, 2016.

On July 14, 2016 CDC, On July 14, 2016, the Centers for Disease Control and Prevention (CDC) MMWR report titled Neisseria gonorrhoeae Antimicrobial Susceptibility Surveillance -The Gonococcal Isolate Surveillance Project, 27 Sites, United States, 2014 which presented the first report to present comprehensive surveillance data from the CDC's sentinel surveillance system to monitor trends in antimicrobial susceptibilities of N. gonorrhoeae, the Gonococcal Isolate Surveillance Project (GISP), and summarized gonorrhea resistance trends over time. This report outlines a concerning trend: resistance levels of gonorrhea to azithromycin, one of the two drugs in the recommended dual therapy treatment for gonorrhea, increased from 0.6 percent in 2013 to 2.5 percent in 2014 (317 percent increase). This is concerning now that this threat is emerging at a time when this common infection continue to fall.

Click here to view more specific details IDPH memorandum insert (PDF).

IAS-USA Recommendations for Antiretroviral Drugs for the Treatment and Prevention of HIV Infection in Adults

International Antiviral Society (IAS-USA), July 12, 2016.

On July 12, 2016 Released JAMA, In a report appearing in the July 12 issue of JAMA, an HIV/AIDS theme issue, Huldrych F. Gunthard, MD, of University Hospital Zurich, Switzerland, and colleagues with the International Antiviral Society-USA (IAS-USA) panel, updated recommendations for the use of antiretroviral therapy in adults with established HIV infection, including when to start treatment, initial regimens, and changing regimens, along with recommendations for using antiretroviral drugs for preventing HIV among those at risk, including preexposure and postexposure prevention. 2016 marks the 20th year since the first IAS-USA modern HIV treatment recommendations were published in JAMA in 1996.

Click here to view more specific details included in the JAMA paper insert (PDF).

Drug Approval: Descovy (emtricitabine (FTC) and tenofovir alafenamide (TAF) fixed-dose combination)

U.S. Food & Drug Administration (FDA), April 5, 2016.

On April 4, 2016 FDA approved DESCOVY, a two-drug fixed dose combination tablet containing 2 HIV nucleoside analog reverse transcriptase inhibitors (NRTIs), emtricitabine (FTC) and tenofovir alafenamide (TAF). Each DESCOVY tablet contains 200 mg of FTC and 25 mg of TAF (equivalent to 28 mg of tenofovir alafenamide fumarate).

DESCOVY is not a complete regimen for the treatment of HIV-1 infection and must be combined with other antiretroviral agents to form a complete regimen.

The approval is based on a relative bioavailability trial demonstrating FTC and TAF exposures were similar between DESCOVY and GENVOYA (elvitegravir/cobicistat/FTC/TAF). A clinical trial to evaluate the efficacy and safety of DESCOVY was not required because the safety and efficacy of FTC and TAF was established previously in clinical trials with GENVOYA.

TAF 25 mg provides for TAF exposures that match or exceed those observed in patients receiving GENVOYA, ensuring adequate antiviral effect. With respect to safety, TAF exposures for FTC/TAF 200 mg/25 mg when used with some boosted protease inhibitors will be higher than that of GENVOYA. However, exposures of the metabolite, tenofovir, will remain substantially lower than that observed with previously approved tenofovir disoproxil fumarate (TDF) formulations such as, Viread (TDF), Truvada (FTC/TDF) and Stribild (Elvitegravir, COBI, FTC, TDF). Thus, the safety of DESCOVY is supported by formulations with substantially higher tenofovir exposures.

Click here to view more specific details included in the DESCOVY package insert (PDF).

April 10th is National Youth HIV/AIDS Awareness Day

National Youth HIV/AIDS Awareness Day focuses the nation's attention on the burden of HIV in youth. The annual observance also spotlights the work of young people across the country in response to the HIV epidemic.

According to the Centers for Disease Control and Prevention (CDC), youth aged 13 to 24 years accounted for an estimated 26% of all new HIV infections in the United States in 2010. CDC estimates that over 50% of youth with HIV in the United States do not know they are infected.

Browse the links on this page to learn more about National Youth HIV/AIDS Awareness Day and to find HIV/AIDS-related information specific to youth.

The official page for NYHAAD: Advocates for Youth

Visit these Federal websites:

Click on the image above for ideas, graphics and resources to help engage youth.

Doctors Report Groundbreaking HIV-to-HIV Organ Transplants

MedlinePlus, U.S. National Library of Medicine, March 31, 2016.

Trailblazing liver and kidney transplants from an HIV-positive donor to HIV-positive recipients were announced Wednesday by surgeons at Johns Hopkins University.

"A couple of weeks ago, we performed the first HIV-to-HIV liver transplant in the world and the first HIV-to-HIV kidney transplant in the United States," Dr. Dorry Segev said during a midday media briefing.

Before 2013 and passage of the HIV Organ Policy Equity Act, this kind of medical advance would not have been possible, because it was illegal for HIV-positive patients to donate organs in the United States. The act allows HIV-positive donors to donate organs to patients infected with the AIDS-causing virus, Segev said.

Until the law was changed, thousands of patients with HIV in need of organ transplants often risked death while waiting for a donated organ, he said.

Click here to read full article on MedlinePlus.